References
1. Sauaia A, Moore FA, Moore EE. Postinjury Inflammation and Organ
Dysfunction. Critical care clinics 2017; 33 :167-91.
2. Levy MM, Rhodes A, Phillips GS, Townsend SR, Schorr CA, Beale R,
Osborn T, Lemeshow S, Chiche JD, Artigas A, Dellinger RP. Surviving
Sepsis Campaign: association between performance metrics and outcomes in
a 7.5-year study. Critical care medicine 2015; 43 :3-12.
3. Efron PA, Mohr AM, Bihorac A, Horiguchi H, Hollen MK, Segal MS, Baker
HV, Leeuwenburgh C, Moldawer LL, Moore FA, Brakenridge SC. Persistent
inflammation, immunosuppression, and catabolism and the development of
chronic critical illness after surgery. Surgery 2018;164 :178-84.
4. Kirchhoff C, Biberthaler P, Mutschler WE, Faist E, Jochum M, Zedler
S. Early down-regulation of the pro-inflammatory potential of monocytes
is correlated to organ dysfunction in patients after severe multiple
injury: a cohort study. Crit Care 2009; 13 :R88.
5. Cheron A, Floccard B, Allaouchiche B, Guignant C, Poitevin F, Malcus
C, Crozon J, Faure A, Guillaume C, Marcotte G, Vulliez A, Monneuse O,
Monneret G. Lack of recovery in monocyte human leukocyte antigen-DR
expression is independently associated with the development of sepsis
after major trauma. Crit Care 2010; 14 :R208.
6. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker
TL, Jarman SD, 2nd, Kreisel D, Krupnick AS, Srivastava A, Swanson PE,
Green JM, Hotchkiss RS. Immunosuppression in patients who die of sepsis
and multiple organ failure. Jama 2011; 306 :2594-605.
7. Horiguchi H, Loftus TJ, Hawkins RB, Raymond SL, Stortz JA, Hollen MK,
Weiss BP, Miller ES, Bihorac A, Larson SD, Mohr AM, Brakenridge SC,
Tsujimoto H, Ueno H, Moore FA, Moldawer LL, Efron PA. Innate Immunity in
the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome
and Its Implications for Therapy. Frontiers in immunology 2018;9 :595.
8. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms,
molecules and clinical significance. Trends Immunol 2009;30 :475-87.
9. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk
HD, Kox W. Monocyte deactivation in septic patients: restoration by
IFN-gamma treatment. Nat Med 1997; 3 :678-81.
10. Nakos G, Malamou-Mitsi VD, Lachana A, Karassavoglou A, Kitsiouli E,
Agnandi N, Lekka ME. Immunoparalysis in patients with severe trauma and
the effect of inhaled interferon-gamma. Critical care medicine
2002; 30 :1488-94.
11. Dries DJ, Jurkovich GJ, Maier RV, Clemmer TP, Struve SN, Weigelt JA,
Stanford GG, Herr DL, Champion HR, Lewis FR, et al. Effect of interferon
gamma on infection-related death in patients with severe injuries. A
randomized, double-blind, placebo-controlled trial. Archives of
Surgery 1994; 129 :1031-41; discussion 42.
12. Polk HC, Jr., Cheadle WG, Livingston DH, Rodriguez JL, Starko KM,
Izu AE, Jaffe HS, Sonnenfeld G. A randomized prospective clinical trial
to determine the efficacy of interferon-gamma in severely injured
patients. Am J Surg 1992; 163 :191-6.
13. Wasserman D, Ioannovich JD, Hinzmann RD, Deichsel G, Steinmann GG.
Interferon-gamma in the prevention of severe burn-related infections: a
European phase III multicenter trial. The Severe Burns Study
Group. Critical care medicine 1998; 26 :434-9.
14. Galbraith N, Walker S, Carter J, Polk HC, Jr. Past, Present, and
Future of Augmentation of Monocyte Function in the Surgical
Patient. Surgical infections 2016; 17 :563-9.
15. Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, Hayden
DL, Hennessy L, Moore EE, Minei JP, Bankey PE, Johnson JL, Sperry J,
Nathens AB, Billiar TR, West MA, Brownstein BH, Mason PH, Baker HV,
Finnerty CC, Jeschke MG, Lopez MC, Klein MB, Gamelli RL, Gibran NS,
Arnoldo B, Xu W, Zhang Y, Calvano SE, McDonald-Smith GP, Schoenfeld DA,
Storey JD, Cobb JP, Warren HS, Moldawer LL, Herndon DN, Lowry SF, Maier
RV, Davis RW, Tompkins RG, Inflammation, Host Response to Injury
Large-Scale Collaborative Research P. A genomic storm in critically
injured humans. J Exp Med 2011; 208 :2581-90.
16. Murphy T, Paterson H, Rogers S, Mannick JA, Lederer JA. Use of
intracellular cytokine staining and bacterial superantigen to document
suppression of the adaptive immune system in injured patients.Annals of surgery 2003; 238 :401-10; discussion 10-1.
17. Licht AK, Schinkel C, Zedler S, Schinkel S, Faist E. Effects of
perioperative recombinant human IFN-gamma (rHuIFN-gamma) application in
vivo on T cell response. J Interferon Cytokine Res 2003;23 :149-54.
18. Laudanski K, Miller-Graziano C, Xiao W, Mindrinos MN, Richards DR,
De A, Moldawer LL, Maier RV, Bankey P, Baker HV, Brownstein BH, Cobb JP,
Calvano SE, Davis RW, Tompkins RG. Cell-specific expression and pathway
analyses reveal alterations in trauma-related human T cell and monocyte
pathways. Proc Natl Acad Sci U S A 2006; 103 :15564-9.
19. Zhang Y, Li J, Lou J, Zhou Y, Bo L, Zhu J, Zhu K, Wan X, Cai Z, Deng
X. Upregulation of programmed death-1 on T cells and programmed death
ligand-1 on monocytes in septic shock patients. Crit Care 2011;15 :R70.
20. Galbraith NJ, O’Brien SJ, Walker SP, Gardner SA, Polk HC, Jr.,
Barnes SL. Temporal expression of circulating miRNA after severe
injury. Surgery 2018; 164 :665-72.
21. Li W, Tu J, Liu X, Yang W. Farnesyltransferase inhibitor FTI-277
inhibits PD-L1 expression on septic spleen lymphocytes and promotes
spleen lymphocyte activation. Clinical and experimental
immunology 2017; 190 :8-18.
22. Patera AC, Drewry AM, Chang K, Beiter ER, Osborne D, Hotchkiss RS.
Frontline Science: Defects in immune function in patients with sepsis
are associated with PD-1 or PD-L1 expression and can be restored by
antibodies targeting PD-1 or PD-L1. Journal of leukocyte biology
2016; 100 :1239-54.
23. Shao R, Fang Y, Yu H, Zhao L, Jiang Z, Li CS. Monocyte programmed
death ligand-1 expression after 3-4 days of sepsis is associated with
risk stratification and mortality in septic patients: a prospective
cohort study. Crit Care 2016; 20 :124.
24. Monaghan SF, Thakkar RK, Tran ML, Huang X, Cioffi WG, Ayala A,
Heffernan DS. Programmed death 1 expression as a marker for immune and
physiological dysfunction in the critically ill surgical patient.Shock 2012; 38 :117-22.
25. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, Swan R, Kherouf
H, Monneret G, Chung CS, Ayala A. PD-1 expression by macrophages plays a
pathologic role in altering microbial clearance and the innate
inflammatory response to sepsis. Proc Natl Acad Sci U S A 2009;106 :6303-8.
26. Hotchkiss RS, Moldawer LL. Parallels between cancer and infectious
disease. The New England journal of medicine 2014;371 :380-3.
27. Monneret G, Gossez M, Venet F. Sepsis in PD-1 light. Crit
Care 2016; 20 :186.
28. Drewry AM, Samra N, Skrupky LP, Fuller BM, Compton SM, Hotchkiss RS.
Persistent lymphopenia after diagnosis of sepsis predicts
mortality. Shock 2014; 42 :383-91.
29. Patil NK, Luan L, Bohannon JK, Hernandez A, Guo Y, Sherwood ER.
Anti-PD-L1 protects against infection with common bacterial pathogens
after burn injury. Journal of leukocyte biology 2018;103 :23-33.
30. Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, Wan X, Deng X, Cai Z.
PD-L1 blockade improves survival in experimental sepsis by inhibiting
lymphocyte apoptosis and reversing monocyte dysfunction. Crit
Care 2010; 14 :R220.
31. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss
RS. Delayed administration of anti-PD-1 antibody reverses immune
dysfunction and improves survival during sepsis. Journal of
leukocyte biology 2010; 88 :233-40.
32. Chang K, Svabek C, Vazquez-Guillamet C, Sato B, Rasche D, Wilson S,
Robbins P, Ulbrandt N, Suzich J, Green J, Patera AC, Blair W, Krishnan
S, Hotchkiss R. Targeting the programmed cell death 1: programmed cell
death ligand 1 pathway reverses T cell exhaustion in patients with
sepsis. Crit Care 2014; 18 :R3.
33. Fallon EA, Biron-Girard BM, Chung CS, Lomas-Neira J, Heffernan DS,
Monaghan SF, Ayala A. A novel role for coinhibitory receptors/checkpoint
proteins in the immunopathology of sepsis. Journal of leukocyte
biology 2018.
34. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression:
from cellular dysfunctions to immunotherapy. Nature reviews
Immunology 2013; 13 :862-74.
35. Heinzelmann M, Polk HC, Jr., Chernobelsky A, Stites TP, Gordon LE.
Endotoxin and muramyl dipeptide modulate surface receptor expression on
human mononuclear cells. Immunopharmacology 2000;48 :117-28.
36. Galbraith NJ, Manek S, Walker S, Bishop C, Carter JV, Cahill M,
Gardner SA, Polk HC, Jr., Galandiuk S. The effect of IkappaK-16 on
lipopolysaccharide-induced impaired monocytes. Immunobiology
2017.
37. Turrel-Davin F, Venet F, Monnin C, Barbalat V, Cerrato E, Pachot A,
Lepape A, Alberti-Segui C, Monneret G. mRNA-based approach to monitor
recombinant gamma-interferon restoration of LPS-induced endotoxin
tolerance. Crit Care 2011; 15 :R252.
38. Cheng SC, Scicluna BP, Arts RJ, Gresnigt MS, Lachmandas E,
Giamarellos-Bourboulis EJ, Kox M, Manjeri GR, Wagenaars JA, Cremer OL,
Leentjens J, van der Meer AJ, van de Veerdonk FL, Bonten MJ, Schultz MJ,
Willems PH, Pickkers P, Joosten LA, van der Poll T, Netea MG. Broad
defects in the energy metabolism of leukocytes underlie immunoparalysis
in sepsis. Nature immunology 2016; 17 :406-13.
39. Livingston DH, Loder PA, Gibson UE, Polk HC. Interferon gamma
administration increases monocyte HLA-DR antigen expression but not
endogenous interferon production. Archives of Surgery 1994;129 .
40. de Kleijn S, Langereis JD, Leentjens J, Kox M, Netea MG, Koenderman
L, Ferwerda G, Pickkers P, Hermans PW. IFN-gamma-stimulated neutrophils
suppress lymphocyte proliferation through expression of PD-L1.PLoS One 2013; 8 :e72249.
41. Rentenaar RJ, de Metz J, Bunders M, Wertheim-van Dillen PM, Gouma
DJ, Romijn JA, Sauerwein HP, ten Berge IJ, van Lier RA. Interferon-gamma
administration after abdominal surgery rescues antigen-specific helper T
cell immune reactivity. Clinical and experimental immunology
2001; 125 :401-8.
42. Ou JN, Wiedeman AE, Stevens AM. TNF-alpha and TGF-beta
counter-regulate PD-L1 expression on monocytes in systemic lupus
erythematosus. Scientific reports 2012; 2 :295.
43. Yee D, Shah KM, Coles MC, Sharp TV, Lagos D. MicroRNA-155 induction
via TNF-alpha and IFN-gamma suppresses expression of programmed death
ligand-1 (PD-L1) in human primary cells. J Biol Chem 2017;292 :20683-93.
44. Payen D, Faivre V, Miatello J, Leentjens J, Brumpt C, Tissieres P,
Dupuis C, Pickkers P, Lukaszewicz AC. Multicentric experience with
interferon gamma therapy in sepsis induced immunosuppression. A case
series. BMC infectious diseases 2019; 19 :931.
45. Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J,
Monneret G, Rimmele T, Blood T, Morre M, Gregoire A, Mayo GA, Blood J,
Durum SK, Sherwood ER, Hotchkiss RS. Interleukin-7 restores lymphocytes
in septic shock: the IRIS-7 randomized clinical trial. JCI
insight 2018; 3 .
46. Hotchkiss RS, Colston E, Yende S, Angus DC, Moldawer LL, Crouser ED,
Martin GS, Coopersmith CM, Brakenridge S, Mayr FB, Park PK, Ye J,
Catlett IM, Girgis IG, Grasela DM. Immune Checkpoint Inhibition in
Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose
Study of Antiprogrammed Cell Death-Ligand 1 Antibody
(BMS-936559). Critical care medicine 2019; 47 :632-42.
47. Of men, not mice. Nature Medicine 2013; 19 :379.
48. Moore FA, Moore EE, Poggetti R, McAnena OJ, Peterson VM, Abernathy
CM, Parsons PE. Gut bacterial translocation via the portal vein: a
clinical perspective with major torso trauma. The Journal of
trauma 1991; 31 :629-36; discussion 36-8.